The authors present the results of a survey of small- and large-molecule pharmaceutical and biopharmaceutical companies on implementation of Analytical quality by design concepts.
Shreekant Karmarkar
Advertisement
Shreekant Karmarkar is a senior research scientist at Baxter.
Articles by Shreekant Karmarkar
A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.
Advertisement
Latest Updated Articles
Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based ApproachPublished: October 2nd 2014 | Updated:
Evaluating Progress in Analytical Quality by DesignPublished: April 2nd 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
2
AI and Human Collaboration Essential for Bio/pharma Innovation
3
Sustainability and Stability in Excipients
4
Centralizing AI Strategy, Ensuring Process Integrity, and Balancing Quick Wins with Long-Term Drug Design in Bio/pharma
5
